About Adamed
About Adamed
Adamed in Poland
Adamed across the globe
Supervisory Board of Adamed Pharma S.A.
Management Team of Adamed Pharma S.A.
Mission and values
Ethics and Compliance
Adamed for the Family
News
Adamed is a pharmaceutical and biotechnology company with 40 years of experience, founded on the basis of Polish scientific advances and a patent portfolio.
Products
Produkty
Prescription drugs
OTC drugs
Dietary supplements
Dermocosmetics
Medical devices
We provide patients with the highest quality medicinal products that are a response to chronic civilization diseases in several therapeutic areas.
Development and innovation
Development and innovation
Research
Development of proprietary medicines
Development of value-added medicines
Business development Startups Requests for proposals and tenders
Innovation is at the core of Adamed’s evolution. It allows us to pursue our mission by responding to the key challenges of modern medicine.
ESG
CSR
Adamed Foundation
Social programmes
Code of Ethics
Responsibility is one of our key values. It is at the core of everything we do and has earned us the trust of patients and the medical community.
Career
Career
Benefits
Development
Locations
Internships and apprenticeships
People are a priority at Adamed, and their passion and dedication has helped us grow into a successful company. Recognising the value of our staff, we are committed to providing excellent work conditions and career opportunities.
Contact

Global English

Popular searches Innovations About Adamed Business Development Adamed worldwide Researches

x

Information on results RFP - 028123 - ORGANISATION AND COMPREHENSIVE MANAGEMENT OF AN ONGOING PHASE I CLINICAL TRIAL (FIRST-IN-HUMAN STUDY)

In connection with co-financing the project "Clinical trial of the first phase (Ia/Ib) of a fusion protein with a dual anticancer mechanism", financed from the State budget by Medical Research Agency (no. 2022/ABM/05/00006-00), acting pursuant to §8 of the co-financing agreement, Adamed Pharma S.A. informs that the order will be awarded to Aurevia Poland Sp. z o.o.